A dose‐adjusted, open‐label, pilot study of the safety, tolerability, and pharmacokinetics of STC3141 in critically ill patients with sepsis
Abstract Increased circulating histones correlate with sepsis severity and are a potential therapeutic target. Pre‐clinical studies showed benefit with a histone‐neutralizing polyanion molecule (STC3141). We aimed to investigate the safety, tolerability, and pharmacokinetics of STC3141 in critically...
| Published in: | Pharmacology Research & Perspectives |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.70015 |
